PCSK9抑制在家族性高胆固醇血症中的疗效与LDL受体功能的关系
该非随机临床试验汇总分析5项3期研究的开放标签扩展阶段数据,纳入703例杂合子家族性高胆固醇血症患者,接受lerodalcibep 300 mg每月皮下注射72周。结果显示第48周和第72周LDL-C平均降低均为50.3%,且降幅与LDLR致病变异的功能活性无关,超过70%患者同时达到LDL-C降低≥50%和基于ASCVD风险的LDL-C目标。
要点
- lerodalcibep在HeFH患者中持续降低LDL-C约50%,疗效不依赖LDLR变异功能活性。
- 超过70%患者同时实现LDL-C降低≥50%及ASCVD风险对应的LDL-C目标。
- 结果支持PCSK9抑制的降LDL-C作用主要由上调未受累的野生型LDLR介导。
核心结论
- lerodalcibep在HeFH患者中显著且持续降低LDL-C,疗效与LDLR致病变异的功能活性无关。
研究设计与样本
- 非随机临床试验,为lerodalcibep全球开放标签3期研究的预设汇总亚分析,纳入703例HeFH患者。
- 参与者来自5项3期研究并进入开放标签扩展研究,时间为2020年12月至2025年5月。
- 所有参与者接受lerodalcibep 300 mg皮下注射每月一次,持续72周。
主要发现
- 703例参与者平均年龄53.8岁(范围18-80),男性372例(52.9%)。
- 基线平均LDL-C为144.9 mg/dL(SD 61.9),尽管多数患者已接受他汀或依折麦布治疗。
- 第48周和第72周LDL-C平均降低均为50.3%(SD分别为28.9%和28.7%),绝对变化分别为-72.6 mg/dL(SD 50.5)和-71.8 mg/dL(SD 48.0)。
- 740例(92.5%)接受基因检测,455例(61.5%)发现单基因FH致病变异,其中432例(95.7%)为LDLR致病变异。
- LDL-C降低与LDLR变异功能活性无关,超过70%参与者同时达到LDL-C降低≥50%和基于ASCVD风险的LDL-C目标。
临床怎么用
- 对于HeFH患者,无论LDLR变异功能活性如何,PCSK9抑制剂lerodalcibep均可考虑用于进一步降低LDL-C。
- 治疗目标可参照基于ASCVD风险的LDL-C目标,并评估LDL-C降低≥50%的达标情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In individuals with heterozygous familial hypercholesterolemia (HeFH), it is uncertain whether and to what extent the reduction in low-density lipoprotein cholesterol (LDL-C) with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy is dependent on the residual functional activity of the LDLR gene carrying the pathogenic variant. OBJECTIVE: To evaluate the reduction in LDL-C achieved with PCSK9 inhibition according to FH genotype in a large cohort of patients with HeFH. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial reports on a predefined, pooled subanalysis of participants with HeFH requiring additional lipid-lowering therapy in the open-label worldwide phase 3 study of the PSCK9 inhibitor lerodalcibep. This study included participants randomized to 5 phase 3 studies with the plasma PSCK9 inhibitor lerodalcibep and who participated in the open-label extension study from December 2020 to May 2025. Data were analyzed from March 2025 to February 2026. INTERVENTION: All participants received lerodalcibep 300 mg subcutaneously monthly for 72 weeks. MAIN OUTCOME AND MEASURES: The co-primary efficacy end points were LDL-C reduction at weeks 48 and 72. Secondary and exploratory end points included LDL-C response according to FH genotype and the achievement of currently recommended LDL-C goals. RESULTS: Among 703 included participants (mean [range] age, 53.8 [18-80] years; 372 male [52.9%]), 86 (12.2%) were Black, South Asian, or multiracial and 617 (87.8%) were White; 217 participants (72.3%) had atherosclerotic cardiovascular disease (ASCVD) or were at very high risk for ASCVD and 195 participants (27.7%) were at high risk for ASCVD. Despite most participants receiving treatment with statins or ezetimibe, the mean (SD) baseline LDL-C was 144.9 (61.9) mg/dL. Mean (SD) reductions in LDL-C associated with lerodalcibep were 50.3% (28.9%) and 50.3% (28.7%) (mean [SD] absolute change, -72.6 [50.5] mg/dL and -71.8 [48.0] mg/dL) at weeks 48 and 72, respectively. Of 740 participants (92.5%) who underwent genetic testing, monogenic FH-causing variants were found in 455 participants (61.5%), including 432 participants (95.7%) with the LDLR pathogenic variant. LDL-C reduction with lerodalcibep was independent of LDLR variant functional activity. More than 70% of participants achieved both a reduction in LDL-C of at least 50% and their ASCVD risk-based LDL-C goal. CONCLUSIONS AND RELEVANCE: These findings suggest that lerodalcibep was associated with significantly and consistently reduced LDL-C in patients with HeFH, with response found to be independent of LDLR function of the pathogenic variant. These findings support that LDL-C reductions in patients with HeFH with PCSK9 inhibition are predominantly mediated by upregulation of the unaffected wild-type LDLR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04798430.
引用
- Raal FJ, Fourie N, Scott R, et al. Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42054033. doi:10.1001/jamacardio.2026.0879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。